Cited by 619Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Open access

Burnett, Alan K., Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert K., Wheatley, Keith·2007·Cancer

DOI 10.1002/cncr.22496

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach. METHODS: Between December 1998 and November 2003, as part of National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, who were deemed unfit for intensive chemotherapy were randomized to receive low‐dose cytarabine (Ara‐C) (20 mg twice daily for 10 days) or hydroxyurea with or without all‐trans retinoic acid (ATRA). RESULTS: Low‐dose ara‐C produced a better remission rate (18% vs 1%; odds ratio [OR], 0.15; 95% confidence interval [95% CI], 0.06–0.37; P = .00006) and better overall survival (OR, 0.60; 95% CI, 0.44–0.81; P = .0009), which was accounted for by the achievement of complete remission (CR) (duration of CR: 80 weeks vs 10 weeks for patients with no CR). Patients who had adverse cytogenetics did not benefit. ATRA had no effect. Toxicity scores or supportive care requirements did not differ between the treatment arms. CONCLUSIONS: Older, less fit patients have a poor outcome, and few trials have been conducted in this patient group. Low‐dose ara‐C treatment was superior to best supportive care and hydroxyurea because it had greater success in achieving CR, and it could represent standard care against which new treatments may be compared in this patient group. [See editorial on pages 000–000, this issue.] Cancer 2007 © 2007 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.22496

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M. E., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 383
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
Menzin, J., Lang, K., Earle, C. C., Kerney, D. L., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259
A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
Cheson, B. D., Jasperse, D. M., Simon, R. M., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1857 · Cited by 210
Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?
Housset, M., Daniel, M., & Degos, L. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb07297.x · Cited by 189
Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose Cytarabine
Wisch, J. S., Griffin, J. D., & Kufe, D. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312293092602 · Cited by 179
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid
Andreeff, M., Jiang, S., Zhang, X., Konopleva, M. Y., Estrov, Z. E., Snell, V., Xie, Z., Okcu, M., Sanchez‐Williams, G., Dong, J., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401573 · Cited by 153
Sexual functioning morbidity among cancer survivors. Current status and future research directions
Andersen, B. L. (1985) · Cancer · doi:10.1002/1097-0142(19850415)55:8 · Cited by 147

Flagged first, then by citations

Show all 26 references

1 of the 26 references couldn’t be matched to a known paper.

Sorted by citations

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,938
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citation
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Juliusson, G., Antunović, P., Derolf, Å. R., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wåhlin, A., & Höglund, M. (2008) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 991
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Acute myeloid leukaemia
Short, N. J., Rytting, M., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 862
Acute myeloid leukemia: current progress and future directions
Kantarjian, H. M., Kadia, T. M., Dinardo, C. D., Daver, N. G., Borthakur, G. M., Jabbour, E., Garcia‐Manero, G., Konopleva, M. Y., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 823
Therapeutic Advances in Acute Myeloid Leukemia
Burnett, A. K., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 806
Self-citation
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Wei, A. H., Montesinos, P., Ivanov, V., Dinardo, C. D., Novák, J., Laribi, K., Kim, I., Stevens, D. A., Fiedler, W., Pagoni, M. N., et al. (2020) · Blood · doi:10.1182/blood.2020004856 · Cited by 793
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Wei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
Dinardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 681
Myelodysplastic Syndromes
Tefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 685
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V. R., Bixby, D. L., Blum, W. G., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 648
Acute myeloid leukaemia
Khwaja, A., Björkholm, M., Gale, R. E., Levine, R. L., Jordan, C. T., Ehninger, G., Bloomfield, C. D., Estey, E. H., Burnett, A. K., Cornelissen, J. J., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.10 · Cited by 636
Self-citation
Acute myeloid leukaemia in adults
Ferrara, F., & Schiffer, C. A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61727-9 · Cited by 573
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Lübbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A. A. N., Selleslag, D., Labar, B., Germing, U., Salih, H. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9245 · Cited by 557
An update of current treatments for adult acute myeloid leukemia
Dombret, H., & Gardin, C. (2015) · Blood · doi:10.1182/blood-2015-08-604520 · Cited by 576
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Cortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O. G., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0312-9 · Cited by 496
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hoelzer, D. T., Bassan, R., Dombret, H., Fielding, A. K., Ribera, J., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 473
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Blum, W. G., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S. M., Liu, S., Havelange, V., Becker, H., Schaaf, L. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002650107 · Cited by 450
Survival for older patients with acute myeloid leukemia: a population-based study
Oran, B., & Weisdorf, D. J. (2012) · Haematologica · doi:10.3324/haematol.2012.066100 · Cited by 423
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Tallman, M. S., Wang, E. S., Altman, J. K., Appelbaum, F. R., Bhatt, V. R., Bixby, D. L., Coutre, S. E., Lima, M. J. G. D., Fathi, A. T., Fiorella, M., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0028 · Cited by 423
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Kantarjian, H. M., Ravandi, F., O'Brien, S. M., Cortes, J. E., Faderl, S. H., Garcia‐Manero, G., Jabbour, E. J., Wierda, W. G., Kadia, T. M., Pierce, S. A., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276485 · Cited by 403
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaïdano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0060 · Cited by 362
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., & Reikvam, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082907 · Cited by 365
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
Flotho, C., Claus, R., Batz, C., Schneider, M., Sandrock, I., Ihde, S., Plass, C., Niemeyer, C. M., & Lübbert, M. (2009) · Leukemia · doi:10.1038/leu.2008.397 · Cited by 316
Acute myeloid leukemia in the real world: why population-based registries are needed
Juliusson, G., Lazarević, V., Hörstedt, A., Hagberg, O., & Höglund, M. (2012) · Blood · doi:10.1182/blood-2011-12-379008 · Cited by 306
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
Krug, U. O., Röllig, C., Koschmieder, A., Heinecke, A., Sauerland, M. C., Schaich, M. A., Thiede, C., Krämer, M., Braess, J., Spiekermann, K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62105-8 · Cited by 304
How I treat acute myeloid leukemia in the era of new drugs
Dinardo, C. D., & Wei, A. H. (2019) · Blood · doi:10.1182/blood.2019001239 · Cited by 293
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Heuser, M., Ofran, Y., Boissel, N., Brunet, S., Craddock, C., Janssen, J. J. W. M., Wierzbowska, A., & Buske, C. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.018 · Cited by 286
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
Sasaki, K., Ravandi, F., Kadia, T. M., Dinardo, C. D., Short, N. J., Borthakur, G. M., Jabbour, E. J., & Kantarjian, H. M. (2021) · Cancer · doi:10.1002/cncr.33458 · Cited by 280
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Swords, R. T., Kelly, K. R., Smith, P. G., Garnsey, J., Mahalingam, D., Medina, E. C., Oberheu, K., Padmanabhan, S., O'Dwyer, M. E., Nawrocki, S. T., et al. (2010) · Blood · doi:10.1182/blood-2009-11-254862 · Cited by 277
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia
Rosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N. D., Divgi, C. R., Panageas, K. S., Heaney, M. L., Chanel, S. M., Morgenstern, A., Sgouros, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0382 · Cited by 272
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
Wheatley, K., Brookes, C. L., Howman, A. J., Goldstone, A. H., Milligan, D. W., Prentice, A. G., Moorman, A. V., & Burnett, A. K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07663.x · Cited by 236
Self-citation
Pevonedistat ( MLN 4924), a First‐in‐Class NEDD 8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
Swords, R. T., Erba, H. P., DeAngelo, D. J., Bixby, D. L., Altman, J. K., Maris, M. B., Hua, Z., Blakemore, S. J., Faessel, H. M., Sedarati, F., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13323 · Cited by 238
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Döhner, H., Lübbert, M., Fiedler, W., Fouillard, L., Haaland, A. K., Brandwein, J. M., Leprêtre, S., Reman, O., Turlure, P., Ottmann, O. G., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560557 · Cited by 233
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Lübbert, M., Rüter, B. H., Claus, R., Schmoor, C., Schmid, M., Germing, U., Kuendgen, A., Rethwisch, V., Ganser, A., Platzbecker, U., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.048231 · Cited by 232
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
Gjertsen, B. T., & Schöffski, P. (2014) · Leukemia · doi:10.1038/leu.2014.222 · Cited by 225
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Schlenk, R. F., Dohner, K., Kneba, M., Gotze, K., Hartmann, F., del Valle, F., Kirchen, H., Koller, E., Fischer, J. T., Bullinger, L., et al. (2009) · Haematologica · doi:10.3324/haematol.13378 · Cited by 210
How I treat the older patient with acute myeloid leukemia
Ossenkoppele, G. J., & Löwenberg, B. (2014) · Blood · doi:10.1182/blood-2014-08-551499 · Cited by 215
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Swords, R. T., Coutre, S. E., Maris, M. B., Zeidner, J. F., Foran, J. M., Cruz, J. C., Erba, H. P., Berdeja, J. G., Tam, W., Vardhanabhuti, S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-805895 · Cited by 203
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Faderl, S. H., Ravandi, F., Huang, X., Garcia‐Manero, G., Ferrajoli, A., Estrov, Z. E., Borthakur, G. M., Verstovšek, S., Thomas, D. A., Kwari, M. I., et al. (2008) · Blood · doi:10.1182/blood-2007-11-124602 · Cited by 199
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
Kantarjian, H. M., Erba, H. P., Claxton, D. F., Arellano, M. L., Lyons, R. M., Kovascovics, T. J., Gabrilove, J. L., Craig, M., Douer, D., Maris, M. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3130 · Cited by 190
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
Kantarjian, H. M., Kadia, T. M., Dinardo, C. D., Welch, M. A., & Ravandi, F. (2021) · Cancer · doi:10.1002/cncr.33477 · Cited by 190
Venetoclax-based therapies for acute myeloid leukemia
Guerra, V. A., Dinardo, C. D., & Konopleva, M. Y. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.008 · Cited by 183
Acute myeloid leukemia—Major progress over four decades and glimpses into the future
Kantarjian, H. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24246 · Cited by 174
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
Murphy, T., & Yee, K. W. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1391216 · Cited by 180
Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
Othus, M. K. D., Kantarjian, H. M., Petersdorf, S. H., Ravandi, F., Godwin, J. E., Cortes, J. E., Pierce, S. A., Erba, H. P., Faderl, S., Appelbaum, F. R., et al. (2013) · Leukemia · doi:10.1038/leu.2013.176 · Cited by 167
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study
Pollyea, D. A., Pratz, K. W., Letai, A. G., Jonas, B. A., Wei, A. H., Pullarkat, V. A., Konopleva, M. Y., Thirman, M. J., Arellano, M. L., Becker, P. S., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26039 · Cited by 167
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
Burnett, A. K., Hills, R. K., Hunter, A., Milligan, D. W., Kell, W. J., Wheatley, K., Yin, J. A. L., McMullin, M. F., Dignum, H., Bowen, D., et al. (2012) · Leukemia · doi:10.1038/leu.2012.229 · Cited by 161
Self-citation
Unlocking the potential of retinoic acid in anticancer therapy
Schenk, T., Stengel, S., & Zelent, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.412 · Cited by 160
Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Strati, P., Kantarjian, H. M., Ravandi, F., Nazha, A., Borthakur, G. M., Daver, N. G., Kadia, T. M., Estrov, Z. E., Garcia‐Manero, G., Konopleva, M. Y., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23924 · Cited by 155
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management
Estey, E. H. (2011) · American Journal of Hematology · doi:10.1002/ajh.22246 · Cited by 158
Acute myeloid leukaemia in the elderly: a review
Pollyea, D. A., Kohrt, H. E. K., & Medeiros, B. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08470.x · Cited by 150
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Harousseau, J., Martinelli, G., Wiktor-Jędrzejczak, W., Brandwein, J. M., Bordessoule, D., Masszi, T., Ossenkoppele, G. J., Alexeeva, J. A., Beutel, G., Maertens, J. A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-198093 · Cited by 149
Self-citation
The success and the challenge of all-trans retinoic acid in the treatment of cancer
Ni, X., Hu, G., & Cai, X. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1509201 · Cited by 149
European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy
Burnett, A. K., Russell, N. H., Kell, J., Dennis, M. W., Milligan, D. W., Paolini, S., Yin, J., Culligan, D. J., Johnston, P., Murphy, J. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4242 · Cited by 147
Self-citation
Acute myeloid leukemia in the older adults
Almeida, A. M., & Ramos, F. (2016) · Leukemia Research Reports · doi:10.1016/j.lrr.2016.06.001 · Cited by 147
Frontline treatment of acute myeloid leukemia in adults
Tamamyan, G., Kadia, T. M., Ravandi, F., Borthakur, G. M., Cortes, J. E., Jabbour, E. J., Daver, N. G., Ohanian, M. N., Kantarjian, H. M., & Konopleva, M. Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.004 · Cited by 151
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Stahl, M. F., DeVeaux, M., Montesinos, P., Itzykson, R., Ritchie, E. K., Sekeres, M. A., Barnard, J., Podoltsev, N. A., Brunner, A. M., Komrokji, R. S., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016121 · Cited by 146
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Rowe, J. M., & Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2013-03-490482 · Cited by 143
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
Estey, E. H. (2013) · Leukemia · doi:10.1038/leu.2013.173 · Cited by 142
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults
Klepin, H. D., Rao, A. V., & Pardee, T. S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1564 · Cited by 146
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo
Miraki‐Moud, F., Ghazaly, E. A., Ariza‐McNaughton, L., Hodby, K. A., Clear, A. J., Anjos‐Afonso, F., Liapis, K., Grantham, M., Sohrabi, F., Cavenagh, J. D., et al. (2015) · Blood · doi:10.1182/blood-2014-10-608133 · Cited by 139
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial
Burnett, A. K., Milligan, D. W., Goldstone, A. H., Prentice, A. G., McMullin, M., Dennis, M. W., Sellwood, E., Pallis, M., Russell, N. H., Hills, R. K., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07604.x · Cited by 139
Self-citation
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
Malfuson, J. V., Etienne, A., Turlure, P., de Revel, T., Thomas, X., Contentin, N., Terré, C., Rigaudeau, S., Bordessoule, D., Vey, N., et al. (2008) · Haematologica · doi:10.3324/haematol.13309 · Cited by 138
Hydroxyurea: a key player in cancer chemotherapy
Madaan, K., Kaushik, D., & Verma, T. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.175 · Cited by 133
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Francia, R. D., Crisci, S., Monaco, A. D., Cafiero, C., Re, A., Iaccarino, G., Filippi, R. D., Frigeri, F., Corazzelli, G., Micera, A., et al. (2021) · Cancers · doi:10.3390/cancers13050966 · Cited by 143
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
Burnett, A. K., Russell, N. H., Hunter, A., Milligan, D. W., Knapper, S., Wheatley, K., Yin, J., McMullin, M. F., Ali, S., Bowen, D., et al. (2013) · Blood · doi:10.1182/blood-2013-04-496596 · Cited by 132
Self-citation
Azacitidine for the treatment of patients with acute myeloid leukemia
Maurillo, L., Venditti, A., Spagnoli, A., Gaïdano, G., Ferrero, D., Olíva, E. N., Lunghi, M., D’Arco, A. M., Levis, A., Pastore, D., et al. (2011) · Cancer · doi:10.1002/cncr.26354 · Cited by 128
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia
Norsworthy, K. J., By, K., Subramaniam, S., Zhuang, L., Valle, P. L. D., Przepiorka, D., Shen, Y. L., Sheth, C. M., Liu, C., Leong, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0365 · Cited by 127
Current status and research directions in acute myeloid leukemia
Kantarjian, H. M., Borthakur, G. M., Daver, N. G., Dinardo, C. D., Issa, G. C., Jabbour, E. J., Kadia, T. M., Sasaki, K., Short, N. J., Yilmaz, M. E., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01143-2 · Cited by 139
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Wei, A. H., & Tiong, I. S. (2017) · Blood · doi:10.1182/blood-2017-08-784066 · Cited by 129
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
Salamero, O., Montesinos, P., Willekens, C., Pérez‐Simón, J. A., Pigneux, A., Récher, C., Popat, R., Carpio, C. D. C., Molinero, C., Mascaró, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03250 · Cited by 126
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
Prassek, V. V., Rothenberg‐Thurley, M., Sauerland, M. C., Herold, T., Janke, H., Ksienzyk, B., Konstandin, N. P., Görlich, D., Krug, U. O., Faldum, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191536 · Cited by 125
Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
Seymour, J. F., Fenaux, P., Silverman, L. R., Mufti, G. J., Hellström‐Lindberg, E., Santini, V., List, A. F., Gore, S. D., Backstrom, J. T., McKenzie, D., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.04.005 · Cited by 117
Acute myeloid leukemia management and research in 2025
Kantarjian, H. M., Dinardo, C. D., Kadia, T. M., Daver, N. G., Altman, J. K., Stein, E. M., Jabbour, E. J., Schiffer, C. A., Lang, A. M., & Ravandi, F. (2024) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21873 · Cited by 134
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Burnett, A. K., Hills, R. K., Green, C. L., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D. W., Goldstone, A. H., et al. (2009) · Blood · doi:10.1182/blood-2009-08-236588 · Cited by 114
Self-citation
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
Al‐Ali, H. K., Jaekel, N., Junghanß, C., Maschmeyer, G., Krahl, R., Cross, M. A., Hoppe, G., & Niederwieser, D. W. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.606382 · Cited by 113
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy
Wass, M., Göllner, S., Besenbeck, B., Schlenk, R. F., Mundmann, P., Göthert, J. R., Noppeney, R., Schliemann, C., Mikesch, J., Lenz, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0892-z · Cited by 106
Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use
Liersch, R., Müller‐Tidow, C., Berdel, W. E., & Krug, U. O. (2014) · British Journal of Haematology · doi:10.1111/bjh.12750 · Cited by 118
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia
Kantarjian, H. M., Martinelli, G., Jabbour, E. J., Quintás‐Cardama, A., Ando, K., Bay, J., Wei, A. H., Gröpper, S., Papayannidis, C., Owen, K., et al. (2013) · Cancer · doi:10.1002/cncr.28113 · Cited by 105
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial
Lübbert, M., Grishina, O., Schmoor, C., Schlenk, R. F., Jost, E., Crysandt, M. M., Heuser, M., Thol, F. R., Salih, H. R., Schittenhelm, M. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01053 · Cited by 102
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Montesinos, P., Roboz, G. J., Bulabois, C., Subklewe, M. S., Platzbecker, U., Ofran, Y., Papayannidis, C., Wierzbowska, A., Shin, H. J., Doronin, V., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0773-5 · Cited by 100
Novel Approaches to the Treatment of Acute Myeloid Leukemia
Roboz, G. J. (2011) · Hematology · doi:10.1182/asheducation-2011.1.43 · Cited by 103
Post-remission therapy for acute myeloid leukemia
Schlenk, R. F. (2014) · Haematologica · doi:10.3324/haematol.2014.114611 · Cited by 100
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
Tan, P., Wei, A. H., Mithraprabhu, S., Cummings, N. J., Liu, H. B., Perugini, M., Reed, K., Avery, S., Patil, S., Walker, P., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2013.68 · Cited by 95
Management of older or unfit patients with acute myeloid leukemia
Walter, R. B., & Estey, E. H. (2014) · Leukemia · doi:10.1038/leu.2014.216 · Cited by 92
Treating acute myeloid leukemia in older adults
Wang, E. S. (2014) · Hematology · doi:10.1182/asheducation-2014.1.14 · Cited by 91
Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia
Sekeres, M. A., Lancet, J. E., Wood, B. L., Grove, L. E., Sandalic, L., Sievers, E. L., & Jurcic, J. G. (2012) · Haematologica · doi:10.3324/haematol.2012.066613 · Cited by 91
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Issa, J. J., Estey, E. H., Keating, M. J., & Freireich, E. J. (2008) · Cancer · doi:10.1002/cncr.23655 · Cited by 90
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
on behalf of the EORTC Leukemia Group and the German MDS Study Group, Lübbert, M., Suciu, S., Hagemeijer, A., Rüter, B. H., Platzbecker, U., Giagounidis, A. A. N., Selleslag, D., Labar, B., Germing, U., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2547-0 · Cited by 88
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Fredly, H., Gjertsen, B. T., & Bruserud, Ø. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-12 · Cited by 87
New strategies to treat AML: novel insights into AML survival pathways and combination therapies
Nair, R., Salinas-Illarena, A., & Baldauf, H. (2020) · Leukemia · doi:10.1038/s41375-020-01069-1 · Cited by 86
Decitabine in the treatment of acute myeloid leukemia in elderly patients
Cashen, A. F., & Malik, P. (2014) · Cancer Management and Research · doi:10.2147/cmar.s40600 · Cited by 86
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
Crump, M., Hedley, D. W., Kamel‐Reid, S., Leber, B. F., Wells, R. W., Brandwein, J. M., Buckstein, R. J., Kassis, J., Minden, M. D., Matthews, J., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903585286 · Cited by 84

Authors: Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K.
Affiliations: Cardiff University (GB)
Heartlands Hospital (GB)
Derriford Hospital (GB)
University College Hospital (GB)
Belfast City Hospital (GB)
Cancer Research UK Clinical Trials Unit (GB)
Corresponding author: Burnett, Alan K.
ORCID: Burnett, Alan K.
Goldstone, Anthony H.
McMullin, Mary F.
Hills, Robert K.
Wheatley, Keith
Venue: Cancer
Publisher: Wiley
Published: 2007-02-21
Volume: 109
Issue: 6
Pages: 1114-1124
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.22496
OpenAlex: W2068556430
Cited by: 619
References: 26
Citations by year: 2026: 5 · 2025: 14 · 2024: 13 · 2023: 23 · 2022: 28 · 2021: 43 · 2020: 45 · 2019: 40 · 2018: 29 · 2017: 37 · 2016: 36 · 2015: 54 · 2014: 48 · 2013: 42 · 2012: 36
FWCI: 18.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Research Portal (Queen's University Belfast) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: acute myeloid leukemia, high-risk myelodysplastic syndrome, low-dose cytarabine, hydroxyurea, all-trans retinoic acid, elderly patients, complete remission, overall survival, adverse cytogenetics, best supportive care
MeSH terms: Acute Disease, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Female, Humans, Hydroxyurea, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Risk, Survival, Tretinoin, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks